Citigroup analyst Patrick Donnelly upgrades Bio-Techne (NASDAQ:TECH) from Neutral to Buy and raises the price target from $81.25 to $100.
Integrative Study Conducted By 10x Genomics Combines Single Cell, Spatial And In Situ Analyses To Investigate Tumor Invasiveness
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platformsPLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ -- 10x
